Skip to content

NASDAQ · large · thesis board

GILD Gilead Sciences

Liver disease portfolio / MASH optionality

View race

Thesis

Editorial summary — not a primary filing

Liver and virology strength; MASH optionality layered on core cash flows.

Next gate

2027-03-15EstimatedPh2 readout

Liver pipeline update

214 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~17 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~730d)100%
Days to gate (214d)29%
Show math

$6.0B cash ÷ $250M/mo burn ≈ 730 days. Source: curated SEC quarter figures.

Cash $6.0B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
MDGLApprovedokAKROPh3okVKTXPh2ok

Risks

  • Pipeline prioritization
  • Competitive liver field
  • HIV franchise maturity
  • BD execution

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT04951219as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01